Tharimmune has raised approximately $540 million in a private placement led by institutional investors, aiming to develop a digital asset treasury strategy centered on Canton Coin. The funds will support token acquisitions and validator operations on the Canton Network, expanding the company’s presence in blockchain infrastructure.
The biotech firm plans to operate multiple validator nodes to earn network rewards while integrating blockchain participation into its broader financial strategy. Executives said the initiative reflects a long-term approach to digital asset management and decentralized finance adoption.
The move marks a major shift for Tharimmune from traditional biotechnology toward crypto-focused treasury diversification.
